Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs.
Femasys has an expansive, internally-created intellectual property portfolio with over 150 patents globally for our product candidates and our products.
Contraception Product Candidate
Research
Preclinical
PMA Clinical Studies
STAGE I
STAGE II
STAGE III
Contraception Product Candidate
Permanent Birth Control and Ultrasound Occlusion Confirmation
Research
Preclinical
PMA Clinical Studies
Anticipated Milestones
- IDE approval achieved from FDA June 2023
- Pivotal trial enrollment initiated August 2023
Infertility Products and Product Candidates
Research
Preclinical
De Novo Clinical Study
INFERTILITY PRODUCTS AND PRODUCT CANDIDATES
Research
Preclinical
De Novo Clinical Study
Research
Preclinical
Approval
Biopsy Product
Research
Preclinical
Approval
Biopsy Product
Endocervical Tissue Sampler
Research
Preclinical
Approval
FemEMB™
Endometrial Biopsy
Permanent Birth Control
FemBloc®
FemBloc is in late-stage clinical development as the first and only in-office approach to permanent birth control without the need for anesthesia or special equipment, which would make this nonsurgical option easy to incorporate into existing practices worldwide. With a potential to be substantially less cost than the long-standing surgical alternative, FemBloc enriches the physician’s practice. FemBloc also features the first and only ultrasound approach to confirm success 90 days after the procedure.
Infertility
FemaSeed®
FemaSeed is a novel solution in late-stage clinical development for insemination that can be performed as a first-line therapeutic option. It would be the first and only directed approach designed to be more affordable than assisted reproduction, such as in vitro fertilization (IVF).
Femvue® | FemCath®
Other Products
FemCerv®
FemCerv is the first and only approach for comprehensive tissue sampling for the diagnosis of cervical cancer. We are marketing this diagnostic option alongside our other female-specific medical products to physicians’ offices.
